Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs)
covalently attached to a cytotoxic drug via a chemical linker. It combines both the …

Antibody–drug conjugates (ADCs) harness the highly specific targeting capabilities of an
antibody to deliver a cytotoxic payload to specific cell types. They have garnered …

Maleimide chemistry stands out in the bioconjugation toolbox by virtue of its synthetic
accessibility, excellent reactivity, and practicability. The second‐generation of clinically …

Peptides are a growing therapeutic class due to their unique spatial characteristics that can
target traditionally “undruggable” protein–protein interactions and surfaces. Despite their …

Chemical protein modification has emerged as an invaluable tool for the development of
modified proteins. The complementary use of both genetic and chemical methods has …

Paper-based lateral flow immunoassays (LFIAs) are one of the most widely used point-of-
care (PoC) devices; however, their application in early disease diagnostics is often limited …

Bioconjugation methodologies have proven to play a central enabling role in the recent
development of biotherapeutics and chemical biology approaches. Recent endeavours in …

The modification of proteins with non‐protein entities is important for a wealth of
applications, and methods for chemically modifying proteins attract considerable attention …

The conjugation of biomolecules can impart materials with the bioactivity necessary to
modulate specific cell behaviors. While the biological roles of particular polypeptide …

Although recent methods for the engineering of antibody–drug conjugates (ADCs) have
gone some way to addressing the challenging issues of ADC construction, significant …